There are 2 clinical trials
Atherosclerosis of the carotid arteries is a common cause of stroke. The prevalence and progression of carotid atherosclerosis are believed to be influenced by genetically inherited variations in lipoprotein metabolism. This study investigates the specific role of paraoxonase, an enzyme thought to detoxify atherogenic oxidized low-density lipoprotein. This study compares veterans who have significant carotid atherosclerosis on ultrasound examination with controls without carotid atherosclerosis. Both paraoxonase activity and genotype will be determined and compared between groups. The results may eventually make it possible to screen for a paraoxonase allele that confers high risk of atherosclerosis, and to diminish the risk by early treatment.
Two paraoxonase (PON1) polymorphisms, PON1-Q192R and PON1-L55M have been inconsistently associated with vascular disease. --- Q192R ---
This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.
Genes which are known to be related with clopidogrel resistance were evaluated; (1-3) CYP 2C19 *2, *3, *17, (4) PON1 Q192R, (5) ABCB1 3435C->T, (6) P2Y12, (7) CYP 2C9 *3. --- Q192R ---
Description: Revascularization of in-stent restenosis which developed in previously implanted stent on index procedureMeasure: Target lesion revascularization Time: 1 year after index procedure
Description: Ischemic or hemorrhagic cerebral infarction diagnosed by brain MRI which developed within 1 year after index procedureMeasure: Stroke Time: 1 year after index procedure
Description: Value which is measured with VerifyNow that can monitor platelet inhibition of clopidogrelMeasure: PRU Time: Within index procedure
Description: Value which is measured with VerifyNow that can monitor platelet inhibition of aspirinMeasure: ARU Time: Within index procedure